(PR-inside.com) http://www.biotherapharma.com - Third graph, second sentence should read 'In the second arm, we expect that patients receiving Imprime PGG and Erbitux alone can achieve positive outcomes without the horrendous side effects of irinotecan chemotherapy' (sted 'with the horrendous side effects of irinotecan chemotherapy'). The corrected release reads: BIOTHERA INITIATES SECOND ARM OF METASTATIC COLORECTAL CANCER TRIAL Biothera announced today it began dosing patients in the second arm of its metastatic colorectal cancer (mCRC) trial in August. This arm of the trial is evaluating the combination therapy of its lead drug candidate, Imprime PGG(R), with Erbitux(R), an anti-cancer ..
More...
More...